Bivalent Delta Omicron BA.5 mRNA COVID-19 Vaccine was Approved for Phase-III Clinical Test in Pakistan

2023-03-14 Source:Aimbio
AIM has made good preparations for the upgrading of COVID-19 vaccines. AIM Vaccine’s bivalent Delta+ Omicron BA.5 mRNA COVID-19 vaccine under development was officially approved for Phase-III clinical test in Pakistan. The results of two clinical researches previously conducted in China indicate good safety, and the results of tests on live virus and antibody show that such vaccine under development can induce high-level neutralizing antibody against Delta, Omicron BA.5, BQ.1, and XBB variants of COVID-19 virus.